Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
Alumis Inc. (NASDAQ: ALMS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Alumis Inc. (NASDAQ: ALMS) had its price target lowered by analysts at HC Wainwright from $30.00 to $26.00. They now have a "buy" rating on the stock.
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements [Yahoo! Finance]
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements